Published on March 29, 2026
The attorneys general of Texas and Arizona have filed a lawsuit against Cord Blood Registry, a major player in the umbilical cord cell storage industry, alleging that the company engaged in false advertising that misled new parents. The suit asserts that Cord Blood Registry profited from deceptive marketing practices, encouraging parents to bank their newborns’ cord blood under the premise of potential medical breakthroughs that may not be scientifically substantiated.
The complaint, filed in a federal court, indicates that Cord Blood Registry’s advertising campaigns touted exaggerated claims regarding the medical benefits of storing umbilical cord blood. These claims led parents to believe that their children could be shielded from a variety of illnesses, including genetic disorders and certain cancers, if they opted to store the cord blood. However, experts argue that while umbilical cord blood can be valuable for certain therapies, the broader claims made Registry lack sufficient scientific backing.
Texas Attorney General Ken Paxton and Arizona Attorney General Kris Mayes emphasized in a joint statement that their investigation revealed the company’s marketing practices fostered a false sense of security among expecting parents. “We will not allow companies to mislead families into making decisions that could have long-term financial consequences,” said Paxton. “Expecting parents deserve to have accurate information about the benefits and limitations of cord blood storage.”
The lawsuit seeks to impose penalties against Cord Blood Registry for consumer fraud and unfair business practices, as well as restitution for families who may have been misled. Additionally, the attorneys general are urging the court to mandate changes in the company’s marketing strategies to ensure that future advertisements provide clear and truthful information regarding the use of umbilical cord blood.
In response to the allegations, Cord Blood Registry released a statement asserting that their practices are compliant with all regulations and that they stand and efficacy of their services. The company claims that it has provided parents with well-researched information and transparent options regarding umbilical cord blood banking.
The outcome of this legal action could have significant implications for the cord blood storage industry as a whole, potentially setting a precedent for how companies market their services and the claims they make to consumers. As the awareness surrounding stem cell therapies and regenerative medicine continues to grow, regulatory scrutiny on the way companies operate in this field is likely to increase.